

# Cooley

March 31, 2010

The recently enacted healthcare reform law created a new program that will provide cash grants and tax credits for certain emerging life sciences companies. The program applies to companies with no more than 250 employees performing qualified research and development during 2009 and 2010.

Only \$1 billion of combined cash grants and tax credits are allocated for the 2-year program, so companies will compete for these benefits by submitting applications to the Treasury Department. Application procedures have not been published as yet, but are expected by the end of May. Cooley will issue additional *Alerts* with details about the application and grant program as they become available. To receive future *Cooley Alerts* on the program, [please register](#).

## Highlights of the program

- Eligible projects (referred to as "qualifying therapeutic discovery projects") include:
  - clinical trials, pre-clinical activities, clinical studies and research protocols undertaken to secure FDA product approval; or
  - projects designed to diagnose diseases or determine molecular factors related to diseases or conditions by developing molecular diagnostics to guide therapeutic decisions; or
  - development of a product, process, or technology to further the delivery or administration of therapeutics.
- The new law provides for a 50% tax credit, or an elective 50% cash grant, for qualifying expenditures on eligible projects certified for acceptance by the Treasury Department in consultation with the Department of Health and Human Services.
- Certain expenditures do not qualify, including interest expense, facility rent and maintenance, and compensation for certain key executives.
- Applications must be submitted and accepted to qualify for either the credit or the cash grant.
- The application for a project will be evaluated based on both medical and economic criteria—particularly the project's potential to:
  - Create new treatments for unmet medical needs,
  - Prevent, detect or treat chronic or acute conditions,
  - Reduce long-term U.S. health care costs, or
  - Significantly advance the goal of curing cancer within the next 30 years, as well as
  - Create and sustain high quality, high-paying U.S. jobs, and
  - Advance U.S. competitiveness in the life sciences.
- Treasury will publish rules for the recapture of credits and grants for projects that cease to be eligible after the grant or credit has been received.
- Expenditures resulting in tax credits or grants under the program will not qualify for certain existing tax benefits, such as the R&D credit, orphan drug credit, or accelerated depreciation deductions.
- Treasury will disclose the identity of, and dollar amount allocated to, each successful applicant.

For more information on the new legislation, please contact any of the attorneys listed above, or your regular Cooley contact.

## Circular 230 Disclosure

The following disclosure is provided in accordance with the Internal Revenue Service's Circular 230 (21 CFR Part 10). Any tax advice contained in this *Alert* is intended to be preliminary, for discussion purposes only, and not final. Any such advice is not intended to be used for marketing, promoting or recommending any transaction or for the use of any person in connection with the preparation of any tax return. Accordingly, this advice is not intended or written to be used, and it cannot be used, by any person for the purpose of avoiding tax penalties that may be imposed on such person.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered **Attorney Advertising** and is subject to our [legal notices](#).

---

## Key Contacts

Jodie Bourdet San Francisco	jbourdet@cooley.com +1 415 693 2054
Christian Plaza Reston	cplaza@cooley.com +1 703 456 8006
Kenneth Krisko Reston	kkrisko@cooley.com +1 703 456 8581
Sonya Erickson Seattle	serickson@cooley.com +1 206 452 8753
Natasha Leskovsek Washington, DC	nleskovsek@cooley.com +1 202 728 7131
Babak (Bo) Yaghmaie New York	byaghmaie@cooley.com +1 212 479 6556

---

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.